ON 01910.Na

• Disease Stage:  Higher-risk MDS Patients
• Status:  Recruiting
• Sponsor:  Onconova Therapeutics, Inc.
• Title: A Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous IV Infusion Every Other Week in MDS Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine.
• Phase:  III
• Purpose:  To compare overall response/survival in patients receiving study drug vs. best supportive care.  Although the mechanism of action of the study drug is not fully known, it is thought to kill cancer cells by two different actions: it stops the tumor cells from dividing and growing, and blocks the proteins involved in cell division causing cells to die. 

Eligibility 

• Diagnosed with MDS, having exhausted current treatment options
• No plans for bone marrow transplant
• Off all other treatment for MDS for at least 4 weeks
• Have/willing to have a central line for IV therapy, if indicated
• Willing and able to adhere to study procedures

Contact:  772-288-5858, option 4

Contact Us

Robert and Carol Weissman Cancer Center
Clinical Research Program
501 E. Osceola St.
Stuart, FL 34994
(772) 288-5858, prompt #4